These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32616528)

  • 1. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.
    Janssen L; Blijlevens NMA; Drissen MMCM; Bakker EA; Nuijten MAH; Janssen JJWM; Timmers S; Hopman MTE
    Haematologica; 2021 Jul; 106(7):1876-1882. PubMed ID: 32616528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy.
    Oswald LB; Hyland KA; Eisel SL; Hoogland AI; Knoop H; Nelson AM; Pinilla-Ibarz J; Sweet K; Jacobsen PB; Jim HSL
    Support Care Cancer; 2022 Jan; 30(1):87-94. PubMed ID: 34231041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
    Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Nakayama T; Takei M; Hatta Y; Nakamura H
    Chemotherapy; 2022; 67(2):96-101. PubMed ID: 34839292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Huang X; Cortes J; Kantarjian H
    Cancer; 2012 Jun; 118(12):3123-7. PubMed ID: 22294282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
    Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rising prevalence of chronic myeloid leukemia in France.
    Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
    Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
    Qi F; Bao M; Gao H; Zhang X; Zhao S; Wang C; Li W; Jiang Q
    Ann Hematol; 2023 Oct; 102(10):2707-2716. PubMed ID: 37578540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
    Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
    Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
    Jim HSL; Hyland KA; Nelson AM; Pinilla-Ibarz J; Sweet K; Gielissen M; Bulls H; Hoogland AI; Jacobsen PB; Knoop H
    Cancer; 2020 Jan; 126(1):174-180. PubMed ID: 31553815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.